(OXYS) Undervalued, High Growth Potential
OxySure Systems, Inc. (OTCBB: OXYS) is an innovative medical device manufacturer that invented a device capable of creating medically pure oxygen from two inert dry powders. The FDA-cleared OxySure Model 615 minimizes many of the risks associated with traditional medical oxygen tanks, is easily operated by a lay person, can be conveniently located on-site next to automated defibrillators (“AEDs”), and has already saved thousands of lives.
With more than 3 million AED installations around the world, there is a large initial market for the OxySure Model 615 that remains untapped. However, beyond the “AED companion” market, there is host of medical emergency categories where oxygen is applicable, not just cardiac arrest. In the long run, the company believes that the OxySure Model 615 could be like a fire extinguisher – that exceeds a 100 million unit market. Management has been working diligently to expand its presence in these markets through a number of initiatives, which have resulted in strong triple-digit top-line growth rates. And, while some investors may see a lofty 20x price-sales ratio, ongoing investments in this growth could justify a much higher share price.
Strong Top-line Performance
OxySure reported revenues of $895,413 during the trailing 12-month period, which is 232% higher than its FY 2012 revenues. In its latest 10-Q filing, management attributed this strong performance to an increase in U.S. product sales, an increase in licensing and service revenues, and an increase in products developed for the military as part of a teaming agreement that combined to boost growth 657% in Q2 2013 alone to $476,071.
Management has sustained this growth through a number of initiatives, including a new double wall cabinet to house a combination AED/OxySure system, a number of new distributors in the U.S., and international distribution agreements with Medizon B.V. and Aero Healthcare. In fact, the company now sells its products through more than 40 distributors and independent agents in the U.S. and overseas in Australia, New Zealand, the Netherlands, Belgium, Luxembourg, the U.K., Brazil, South Africa, Turkey and numerous other markets.
Figure 1 – OxySure Revenue Estimates – Source: Taglich Brothers http://biotechstocktrader.com/wp-content/uploads/2013/10/OXYS-IMG1-10232013.png
Taglich Brothers analysts expect these developments and ongoing organic growth to drive revenues from nearly $2 million this year to $4.9 million in FY 2015, according to an August 19th research note. Over the long-term, the analyst expects FY 2017 revenues to scale up to $18 million based on the acceptance of the company’s Model 615 as a companion to AEDs produced by companies like Johnson & Johnson (NYSE: JNJ) and St. Jude Medical Inc. (NYSE: STJ).
Potential Near-term Profitability
OxySure’s total operating expenses grew just 30% TTM compared to its 232% revenue growth over the same timeframe. These dynamics, along with lower interest expense, helped reduce its net loss for the trailing 12-month period to $(646,271) or $(0.03) per share. And while the company’s cash burn expanded, a closer look reveals that this was due to an increase in accounts receivables and inventory, as well as additional working capital needed to support its growth.
Taglich Brothers expects the company to break even on both a net income and cash flow basis towards the middle to end of FY 2015. While this may seem a bit into the future, it’s worth noting that much of the net loss is due to cost of capital needed to support triple-digit revenue growth. Management could forego these investments in growth and become profitable much sooner, but these higher growth rates could unlock significant margin potential in the stock.
Figure 2 – OxySure Cash Flow Projections – Source: Taglich Brothers http://biotechstocktrader.com/wp-content/uploads/2013/10/OXYS-IMG2-10232013.png
The company also appears significantly undervalued when looking at the potential growth rates from this spending in the near-term, suggesting that the market isn’t fully appreciating these investments in its future growth. While the stock trades with a 20x price-sales ratio right now, the discounted value of its future sales indicate that it might be undervalued. For instance, if revenues hit $0.63 per share in FY 2017, the stock could be worth $4.40 with a mere 7x ratio.
Investment Opportunity
Ultimately, OxySure’s long-term opportunity lies in the large and growing market for AEDs, with over 2.2 million installed worldwide, primarily in the U.S. and Japan. Capturing just a fraction of this market could equate to significant revenue potential, while there is evidence to suggest that medical oxygen is used and must be replaced more frequently. These replacements add recurring revenue to the company’s business model, making it even more attractive long-term.
When quantifying this opportunity, investors may look towards three analysts covering the stock, including Taglich Brothers with a $2.10 price target, Zacks Investment Research with a $1.75 price target, and Sterling Investment Services with a $1.90 price target. Averaging these price targets yields an estimated $1.91 per share 12-month target, which represents a significant 190% premium over the current market price of $0.66 per share.
More Information:
Company Website – http://www.oxysure.com/
Recent SEC Filings – http://secfilings.com/SearchResults.aspx?name=Oxysure%20Systems%20Inc
About Emerging Growth LLC:
EGC is a marketing and consulting firm that specializes in creating ongoing communications strategies for public and private companies.
Disclosure:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx
TraderPower Featured Companies
Top Small Cap Market News
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Closes on $8.2M Private Placement
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
Recent Posts
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
Recent Comments
Archives
- October 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009